N/A
N=2,164
Use of Behavioral Economics in Repeat SARS-CoV-2 (COVID-19) Antibody Testing in Disadvantaged Communities
SARS-CoV-2
Bottom Line
View on ClinicalTrials.gov: NCT04901624 ↗Enrolled (actual)
2,164
Serious AEs
0.0%
Results posted
Aug 2024
Primary outcome: Primary: Attendance Rate at Time 2 SARS-CoV-2 Antibody Test — 123; 84; 129; 78 Participants — p=0.003
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Family Risk Messaging (Behavioral); Personal Risk Messaging (Behavioral); Loss Protection (Behavioral); Lottery Incentive (Behavioral)
- Age
- Pediatric, Adult, Older Adult · 5+ yrs
- Sex
- All
- Sponsor
- University of Southern California
- Primary completion
- Jun 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Attendance Rate at Time 2 SARS-CoV-2 Antibody Test |
123; 84; 129; 78 | 0.003 sig |
| SECONDARY Social and Behavioral Determinants of Antibody Testing |
12; 21; 17; 10; 49; 47 | 0.409 |
Summary
Repeat testing for SARS-CoV-2 antibodies in disadvantaged communities will help identify active and recovered infections over time, and as more is understood about antibody protection, it may help identify persons who have immunity. Many questions about social barriers and behavioral facilitators remain unanswered. This project aims to evaluate the effectiveness of risk-based messaging and incentives that promote repeated testing for SARS-CoV-2 antibodies, as well as to understand social and behavioral determinants of COVID-19 testing and variations within sub-groups of this population.
Eligibility Criteria
Inclusion Criteria
- Adults and children 5 years of age and older
Exclusion Criteria
- Children under 5 years of age
Data sourced from ClinicalTrials.gov (NCT04901624). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.